• DNDi_Logo_No-Tagline_Full Colour
  • Our work
    • Diseases
      • Sleeping sickness
      • Visceral leishmaniasis
      • Cutaneous leishmaniasis
      • Chagas disease
      • Filaria: river blindness
      • Mycetoma
      • Paediatric HIV
      • Cryptococcal meningitis
      • Hepatitis C
      • Dengue
      • Pandemic preparedness
      • Antimicrobial resistance
    • Research & development
      • R&D portfolio & list of projects
      • Drug discovery
      • Translational research
      • Clinical trials
      • Registration & access
      • Treatments delivered
    • Advocacy
      • Open and collaborative R&D
      • Transparency of R&D costs
      • Pro-access policies and IP
      • Children’s health
      • Gender equity
      • Climate change
      • AI and new technologies
  • Networks & partners
    • Partnerships
      • Our partners
      • Partnering with us
    • Global networks
      • Chagas Platform
      • Dengue Alliance
      • HAT Platform
      • LEAP Platform
      • redeLEISH Network
    • DNDi worldwide
      • DNDi Switzerland
      • DNDi DRC
      • DNDi Eastern Africa
      • DNDi Japan
      • DNDi Latin America
      • DNDi North America
      • DNDi South Asia
      • DNDi South-East Asia
  • News & resources
    • News & stories
      • News
      • Stories
      • Statements
      • Viewpoints
      • Social media
      • eNews Newsletter
    • Press
      • Press releases
      • In the media
      • Podcasts, radio & TV
    • Resources
      • Scientific articles
      • Our publications
      • Videos
    • Events
  • About us
    • About
      • Who we are
      • How we work
      • Our strategy
      • Our donors
      • Annual reports
      • Our prizes and awards
      • Our story: 20 years of DNDi
    • Our people
      • Our leadership
      • Our governance
      • Contact us
    • Work with us
      • Working at DNDi
      • Job opportunities
      • Requests for proposal
  • Donate
  • DNDi_Logo_No-Tagline_Full Colour
  • Our work
    • Diseases
      • Sleeping sickness
      • Visceral leishmaniasis
      • Cutaneous leishmaniasis
      • Chagas disease
      • Filaria: river blindness
      • Mycetoma
      • Paediatric HIV
      • Cryptococcal meningitis
      • Hepatitis C
      • Dengue
      • Pandemic preparedness
      • Antimicrobial resistance
    • Research & development
      • R&D portfolio & list of projects
      • Drug discovery
      • Translational research
      • Clinical trials
      • Registration & access
      • Treatments delivered
    • Advocacy
      • Open and collaborative R&D
      • Transparency of R&D costs
      • Pro-access policies and IP
      • Children’s health
      • Gender equity
      • Climate change
      • AI and new technologies
  • Networks & partners
    • Partnerships
      • Our partners
      • Partnering with us
    • Global networks
      • Chagas Platform
      • Dengue Alliance
      • HAT Platform
      • LEAP Platform
      • redeLEISH Network
    • DNDi worldwide
      • DNDi Switzerland
      • DNDi DRC
      • DNDi Eastern Africa
      • DNDi Japan
      • DNDi Latin America
      • DNDi North America
      • DNDi South Asia
      • DNDi South-East Asia
  • News & resources
    • News & stories
      • News
      • Stories
      • Statements
      • Viewpoints
      • Social media
      • eNews Newsletter
    • Press
      • Press releases
      • In the media
      • Podcasts, radio & TV
    • Resources
      • Scientific articles
      • Our publications
      • Videos
    • Events
  • About us
    • About
      • Who we are
      • How we work
      • Our strategy
      • Our donors
      • Annual reports
      • Our prizes and awards
      • Our story: 20 years of DNDi
    • Our people
      • Our leadership
      • Our governance
      • Contact us
    • Work with us
      • Working at DNDi
      • Job opportunities
      • Requests for proposal
  • Donate
Home > Research and development > Portfolio

Visceral leishmaniasis 

GSK245 (DDD1305143)

objective

Progress development of the GSK245 (DDD1305143) compound for leishmaniasis.

project start
2017

current phase of drug development

Discovery project phase
Drug Discovery
Translation project phase
Translational research
clinical trials icon
Clinical trials
Treatment Access
Registration & access

updated 24 Feb 2025

In April 2017, DNDi and GSK entered into an agreement for the pre-clinical development of two compounds  for leishmaniasis: GSK245 (formerly GSK245/DDD1305143) and DNDi-6899 (formerly GSK899/DDD853651). The compounds were developed through a collaboration between the GSK Global Health Unit and the Drug Discovery Unit at the University of Dundee, with co-funding support from Wellcome. In February 2020, DNDi and GSK signed a development and license agreement for GSK245 (DDD1305143).

Project updates

2024

GSK is the sponsor of a Phase I study in healthy volunteers in the UK that was completed in 2024. This drug candidate shares a similar mode of action with LXE408, the frontrunner in DNDi’s portfolio of NCEs under development for leishmaniasis.

2023

The development of GSK245 continues and GSK is the sponsor of a Phase I clinical study in healthy volunteers in the UK. The single ascending dose part of the study has been completed. This drug candidate shares a similar mode of action with LXE408, the frontrunner in DNDi’s portfolio of NCEs under development for leishmaniasis.

2022

GSK put the Phase I single ascending dose trial of GSK245 (DDD1305143) on hold in 2022 to perform additional investigations into the compound’s complex pharmacokinetics. The Phase I study of the compound is expected to resume and complete in early 2023. 

2021

A Phase I combined single ascending dose and multiple ascending dose study of GSK3494245/DDD1305143 in healthy volunteers began in late 2020 and continued in 2021, but faced delays due to the COVID-19 pandemic. It is now expected to be completed by mid-2022. 

2020

A Phase I single ascending dose study of GSK3494245/DDD1305143 in healthy volunteers began in late 2020 and is expected to be completed by Q3 2021. 

2019

A Phase I single ascending dose study of GSK3494245/DDD1305143 is planned to start in late 2020. 

2018

GSK3494245/DDD1305143 is currently under review to assess the feasibility of proceeding to a Phase I study.

News & resources

  • 27 March 2018 – DNDi, GlaxoSmithKline, and University of Dundee to identify drug candidates to treat leishmaniasis and Chagas disease

Partners

  • GlaxoSmithKline (GSK), UK
  • GlaxoSmithKline (GSK) – Spain, Spain
  • University of Dundee, Drug Discovery Unit, UK
Loading…
  • GlaxoSmithKline (GSK)
  • ,UK
  • GlaxoSmithKline (GSK) – Spain
  • ,Spain
  • University of Dundee, Drug Discovery Unit
  • ,UK
  • University of Dundee, Drug Discovery Unit, UK
  • GlaxoSmithKline (GSK) – Spain, Spain
  • GlaxoSmithKline (GSK), UK

Funding

  • Germany - Federal Ministry of Education and Research (BMBF) through KfW
  • Switzerland - Swiss Agency for Development and Cooperation (SDC)
  • The Netherlands - Dutch Ministry of Foreign Affairs (DGIS)
  • UK - UK International Development
​
  • Médecins Sans Frontières International
  • Other private foundations and individuals
  • Wellcome
​

Stay connected

Get our latest news, personal stories, research articles, and job opportunities. 

Linkedin-in Instagram Twitter Facebook-f Youtube
International non-profit developing safe, effective, and affordable treatments for the most neglected patients.

Learn more

  • Diseases
  • Neglected tropical diseases
  • R&D portfolio
  • Policy advocacy

Get in touch

  • Our offices
  • Contact us
  • Integrity Line

Support us

  • Donate
  • Subscribe to eNews

Work with us

  • Join research networks
  • Jobs
  • RFPs
  • Terms of Use   
  •   Acceptable Use Policy   
  •   Privacy Policy   
  •   Cookie Policy   
  •   Our policies   

  • Except for images, films and trademarks which are subject to DNDi’s Terms of Use, content on this site is licensed under a Creative Commons Attribution-NonCommercial-Share Alike 3.0 Switzerland License